Share
Dr. Enoch Kariuki
Pheon Therapeutics, a leading developer of next-generation Antibody-Drug Conjugates (ADCs) for hard-to-treat cancers, has appointed Dr. Enoch Kariuki, Pharm.D., to its Board of Directors as an independent, non-executive director.
Dr. Kariuki brings extensive strategic, operational, and financial expertise from his leadership roles in the biotech industry. Most recently, he served as CEO of Lengo Therapeutics, acquired by Blueprint Medicines, and as CFO of VelosBio, acquired by Merck. His background also includes key positions at Synthorx and board roles at Imago Biosciences and ProfoundBio.
Cyrus Mozayeni, MD, CEO of Pheon, welcomed Dr. Kariuki at a critical growth stage as the company moves its lead ADC program, PHN-010, into clinical trials for advanced solid tumors. Dr. Kariuki expressed excitement about joining Pheon’s mission to advance transformative therapies in oncology.
